Caxton Associates LLP Dyne Therapeutics, Inc. Transaction History
Caxton Associates LLP
- $2.87 Trillion
- Q1 2025
A detailed history of Caxton Associates LLP transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Caxton Associates LLP holds 14,972 shares of DYN stock, worth $174,872. This represents 0.01% of its overall portfolio holdings.
Number of Shares
14,972Holding current value
$174,872% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding DYN
# of Institutions
217Shares Held
116MCall Options Held
322KPut Options Held
66.2K-
Janus Henderson Group PLC London, X010.4MShares$121 Million0.06% of portfolio
-
Ra Capital Management, L.P. Boston, MA9.71MShares$113 Million2.11% of portfolio
-
Atlas Venture Life Science Advisors, LLC9.13MShares$107 Million27.97% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.41MShares$86.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$86.3 Million0.01% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $605M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...